************************************************************************

Size: px
Start display at page:

Download "************************************************************************"

Transcription

1 CARDIOLOGY SMMC : MARINER: Medically Ill Patient Assessment of Rivaroxaban Versus Placebo In Reducing Post-Discharge Venous Thrombo-Embolism Risk Principal Investigator: George Heyrich, MD SMMC : RE-VERSE-AD (A study of the RE-VERSal Effects of Idarucizumab on Active Dabigatran) trial Principal Investigator: Ronald Fields, MD INTERVENTIONAL CARDIOLOGY SMMC : Closure of Patent Foramen Ovale with PFO ACCESS Registry Principal Investigator: Rakesh Shah, MD Clinical Coordinator: Kim Devine, CRNP, CCRP CARDIOTHORACIC / CRITICAL CARE SMMC : IP Bolton Medical, Inc Post-Approval Study of the Relay Thoracic Stent-Graft with Plus Delivery System in Patients with Thoracic Aortic Aneurysms and Penetrating Ulcers Principal Investigator: David Drucker, MD CRITICAL CARE SMMC : IP Bolton Medical, Inc Post-Approval Study of the Relay Thoracic Stent-Graft with Plus Delivery System in Patients with Thoracic Aortic Aneurysms and Penetrating Ulcers Principal Investigator: David Drucker, MD

2 SMMC : EXPANDED ACCESS IND FECAL MICROBIAL TRANSPLANTATION Principal Investigator: Donald Marcus, MD SMMC : MARINER: Medically Ill Patient Assessment of Rivaroxaban Versus Placebo In Reducing Post-Discharge Venous Thrombo-Embolism Risk Principal Investigator: George Heyrich, MD ENDOCRINE / DIABETES MANAGEMENT SMMC : BMS Clinical Protocol MB A Multicenter, Randomized, Double-Blind, Placebo-controlled, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of Dapagliflozin as an Add-on to Insulin Therapy in Subjects with Type 1 Diabetes Mellitus Principal Investigator: Alan Schorr, DO Clinical Coordinator: Miki Haas, RN, BS EMERGENCY DEPARTMENT ELECTROPHYSIOLOGY SMMC : World-wide Randomized Antibiotic EnveloPe Infection PrevenTion Trial (WRAP-IT) Principal Investigator: Scott Burke, MD Research Advisor: MarciPetrino, CRNP, CCRP GENERAL MEDICINE

3 GYNECOLOGY HUMANITARIAN DEVICE EXEMPTIONS SMMC : JOSTENT Coronary Stent Graft and JOSTENT GraftMaster for the treatment of free perforation, defined as free contrast extravasation into the pericardium, in native coronary vessels or saphenous vein bypass grafts 2.75 mm in diameter Principal Investigator: Ronald Fields, MD SMMC : Closure of Patent Foramen Ovale with PFO ACCESS Registry Principal Investigator: Rakesh Shah, MD SMMC : CODMAN ENTERPRISE Vascular Reconstruction Device and Delivery System Principal Investigator: Robert Rosenwasser, MD SMMC : Wingspan Stent System with Gateway PTA Balloon Catheter Principal Investigator: Robert Rosenwasser, MD SMMC : Neuroform Microdelivery Stent System Principal Investigator: Robert Rosenwasser, MD

4 INFECTIOUS DISEASE SMMC : EXPANDED ACCESS IND FECAL MICROBIAL TRANSPLANTATION Principal Investigator: Doanld Marcus, MD OBESITY PEDIATRICS NEUROSURGICAL NEUROVASCULAR SMMC : Closure of Patent Foramen Ovale with PFO ACCESS Registry Principal Investigator: Rakesh Shah, MD SMMC : MaRiss: Mild and Rapidly Improving Stroke Study Principal Investigator: Howard Natter, MD Research Advisor: Marci Petrino, RN, BSN, CCRP

5 PULMONARY RENAL DISEASE VASCULAR INTERVENTION SMMC : MARINER: Medically Ill Patient Assessment of Rivaroxaban Versus Placebo In Reducing Post-Discharge Venous Thrombo-Embolism Risk Principal Investigator: George Heyrich, MD SMMC : Tack Optimized Balloon Angioplasty Study for the Superficial Femoral and Proximal Popliteal Arteries Using the Tack Endovascular System (TOBA II) Principal Investigator: Rakesh Shah, MD WOUND MANAGEMENT

6 ONCOLOGY BLADDER BRAIN BREAST SMMC : Prospective Registry of MammaPrint in Breast Cancer Patients with an Intermediate Score (PROMIS) Clinical Coordinator: Christine Armetta, BS, MBA, CCRP SMMC : Survivor Study: Evaluating Cancer Survivorship Care Models Principal Investigator: Jennifer Torres, RN, BSN, OCN, CCRP Clinical Coordinator: Jennifer Torres, RN, OCN SMMC : ECOG-ACRIN EA1131: A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple Negative Basal-Like Breast Cancer Following Neo-adjuvant Chemotherapy Clinical Coordinator: Jennifer Torres, RN, BSN, OCN, CCRP Opening to Enrollment November 1, 2015 SMMC : E3108/SMMC12006 A phase II prospective trial correlating progression free survival with CYP2D6 activity in patients with metastatic breast cancer treated with single agent Tamoxifen Clinical Coordinator: Christine Armetta, BS, MBA, CCRP Suspended at this time to enrollment

7 SMMC : PUMA A study of Neratinib plus Capecitabine vs Lapatinib plus Capecitabine in patients with HER2+ metastatic breast cancer who have received two or more prior HER2-directed regimens in the metastatic setting (NALA) Clinical Coordinators: Christine Armetta, BS, MBA, CCRP SMMC : Celldex Protocol CDX A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The METRIC Study) Clinical Coordinator: Jennifer Torres, RN, BSN, OCN, CCRP SMMC : Survivor Study: Evaluating Cancer Survivorship Care Models Principal Investigator: Jennifer Torres, RN, BSN, OCN, CCRP Clinical Coordinator: Christine Armetta, BS, MBA, CCRP Closing to Enrollment December 31, 2015 CERVIX CHEMOPREVENTION COLORECTAL ENDOMETRIAL. GASTRIC OR GASTROSOPHAGEAL

8 HEAD AND NECK/LARYNX SMMC : R0920/SMMC11016 A phase III study of postoperative radiation therapy (IMRT) +/- Cetuximab for locally advanced resected head and neck cancer Clinical Coordinators: Jennifer Torres, RN, BSN, OCN, CCRP LEUKEMIA. LUNG SMMC : An Open-Label, Trial of Nivolumab and Nivolumab Plus Ipilimumab Versus Platinum Doublet Chemotherapy in Subjects With Stage IV Non-Small Cell Lung Cancer (NSCLC) (CheckMate 227) Clinical Coordinators: Jennifer Torres, RN, BSN, OCN, CCRP LYMPHOMA MELANOMA MULTIPLE MYELOMA OVARIAN

9 PANCREATIC SMMC : INCB A Randomized, Double-Blind, Phase 3 Study of the JAK1/2 Inhibitor Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy (The JANUS 2 Study) Clinical Coordinators: Jennifer Torres, RN, BSN, OCN, CCRP PROSTATE SMMC : RTOG 0815/SMMC A phase III prospective randomized trial of dose-escalated radiotherapy with or without short-term androgen deprivation therapy for patients with intermediate-risk prostate cancer Clinical Coordinators: Christine Armetta, BS, MBA, CCRP SMMC : ALLIANCE A Phase III trial of Enzalutamide (NSC # ) vs Enzalutamide, Abiraterone and Prednisone for castration resistant metastatic prostate cancer Clinical Coordinator: Jennifer Torres, RN, BSN, OCN, CCRP SMMC : Astellas TRUMPET: A Prospective Observational Cohort Study of Patients with Castration-Resistant Prostate Cancer (CRPC) in the United States. Clinical Coordinator: Jennifer Torres, RN, BSN, OCN, CCRP RECTAL/ANUS REGISTRY

10 SMMC : Observational Clinical Study Protocol CBIO-BB037.V.1 Observational Study: Collection of Human Specimens for Future Scientific and Medical Research Principal Investigator: Dr. Katz Clinical Coordinator: Jennifer Torres, RN, BSN, OCN, CCRP

All Studies by Indication

All Studies by Indication Therapeutic Area Protocol Number Drug/Device Phase Description Advanced malignancies 337 20101132 AMG 337 I " A Phase 1, First-in-Human Study Evaluating the Safety, Tolerability, and Pharmacokinetics of

More information

Studies proceeding under pre HRA-Approval system (NHS Permission)

Studies proceeding under pre HRA-Approval system (NHS Permission) 15/NW/0004 162679 Studies proceeding under pre HRA-roval system (NHS Permission) A MULTI-CENTRE RANDOMISED CLINICAL TRIAL OF BIOMARKER-DRIVEN MAINTENANCE TREATMENT FOR FIRST- LINE METASTATIC COLORECTAL

More information

How do I use mechanical debulking for the treatment of arterial occlusions

How do I use mechanical debulking for the treatment of arterial occlusions How do I use mechanical debulking for the treatment of arterial occlusions Sven Bräunlich, MD Division of Interventional Angiology University-Hospital Leipzig, Germany Disclosure Speaker name: Sven Bräunlich

More information

CLINICAL TRIALS ACC. Jul 2016

CLINICAL TRIALS ACC. Jul 2016 CLINICAL TRIALS ACC Jul 2016 Glioblastoma BRAIN A071102 A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation

More information

CLINICAL TRIALS Open clinical uro-oncology trials in Canada George Rodrigues, MD, Eric Winquist, MD

CLINICAL TRIALS Open clinical uro-oncology trials in Canada George Rodrigues, MD, Eric Winquist, MD Open clinical uro-oncology trials in Canada George Rodrigues, MD, Eric Winquist, MD London Health Sciences Centre, London, Ontario, Canada bladder cancer AN OPEN-LABEL, MULTICENTER, RANDOMIZED PHASE II

More information

WASHINGTON. Spokane Cheney. Olympia. Tri-Cities. Walla Walla. Portland North Central Oregon City OREGON. Mt. Vernon. Port Angeles

WASHINGTON. Spokane Cheney. Olympia. Tri-Cities. Walla Walla. Portland North Central Oregon City OREGON. Mt. Vernon. Port Angeles 2 3 Mt. Vernon Port Angeles Bremerton Tacoma 5 5 Olympia Everett Edmonds Seattle 90 WASHINGTON 90 Spokane Cheney Pullman Longview 82 Tri-Cities Portland North Central Oregon City 5 84 OREGON Walla Walla

More information

ANIL K. CHAGARLAMUDI, M.D. CURRICULUM VITAE

ANIL K. CHAGARLAMUDI, M.D. CURRICULUM VITAE ANIL K. CHAGARLAMUDI, M.D. CURRICULUM VITAE PERSONAL DATA: DATE OF BIRTH: April 23, 1959 PLACE OF BIRTH: Amalapuam, A.P., India EDUCATION: COLLEGE: Andhra Christian College BS Degree Andhra Loyola College

More information

The Clinical Research E-News

The Clinical Research E-News The Clinical Research E-News Volume 7: ISSUE 1: January 16, 2015 Jefferson Kimmel Cancer Center Network: For urgent clinical trial questions or assistance please page: 877-656-9004 New Featured Trials

More information

Open clinical uro-oncology trials in Canada Eric Winquist, MD, George Rodrigues, MD

Open clinical uro-oncology trials in Canada Eric Winquist, MD, George Rodrigues, MD Open clinical uro-oncology trials in Canada Eric Winquist, MD, George Rodrigues, MD London Health Sciences Centre, London, Ontario, Canada BLADDER CANCER A MULTICENTRE, RANDOMIZED PLACEBO-CONTROLLED, DOUBLE-BLIND

More information

Rotarex mechanical debulking: The Leipzig experience in patients

Rotarex mechanical debulking: The Leipzig experience in patients Rotarex mechanical debulking: The Leipzig experience in 1.200+ patients Dierk Scheinert, MD Division of Interventional Angiology University-Hospital Leipzig, Germany Disclosure Speaker name: Dierk Scheinert

More information

Outcomes Report: Accountability Measures and Quality Improvements

Outcomes Report: Accountability Measures and Quality Improvements Outcomes Report: Accountability Measures and Quality Improvements The FH Memorial Medical Center s Cancer Committee ensures that patients with cancer are treated according to the nationally accepted measures.

More information

The Clinical Research E-News

The Clinical Research E-News Volume 4: ISSUE 6: August 28, 2012 The Clinical Research E-News Jefferson Kimmel Cancer Center Network: For urgent clinical trial questions or assistance please page: 877-656-9004 New Trials Opened at

More information

Comparison Of Primary Long Stenting Versus Primary Short Stenting For Long Femoropopliteal Artery Disease (PARADE)

Comparison Of Primary Long Stenting Versus Primary Short Stenting For Long Femoropopliteal Artery Disease (PARADE) Comparison Of Primary Long Stenting Versus Primary Short Stenting For Long Femoropopliteal Artery Disease (PARADE) Young-Guk Ko, M.D. Severance Cardiovascular Hospital, Yonsei University Health System,

More information

Selected tables standardised to Segi population

Selected tables standardised to Segi population Selected tables standardised to Segi population LIST OF TABLES Table 4.2S: Selected causes of death, all-ages, 2000 2004 (Segi Standard) Table 5.3S: Public hospitalisations by major cause of admission

More information

HSHS St. Vincent Hospital Regional Cancer Center Adult Active Study List

HSHS St. Vincent Hospital Regional Cancer Center Adult Active Study List NHLBI-MDS ECOG-A NCT02775383 Blood Disorders-Other The National Myelodysplastic Syndromes (MDS) Study PNH Registry M07-001 DRUG CO NCT01374360 Blood Disorders-Other PNH Registry A071102 ALLIANCE NCT02152982

More information

Endovascular Repair of Aortic Arch/Thoracic Aneurysms: Bolton RelayBranch Device

Endovascular Repair of Aortic Arch/Thoracic Aneurysms: Bolton RelayBranch Device Endovascular Repair of Aortic Arch/Thoracic Aneurysms: Bolton RelayBranch Device Luis A. Sanchez MD Gregorio A. Sicard Distinguished Professor of Surgery & Radiology Chief, Section of Vascular Surgery

More information

Corporate Medical Policy

Corporate Medical Policy Corporate Medical Policy Endovascular Therapies for Extracranial Vertebral Artery Disease File Name: Origination: Last CAP Review: Next CAP Review: Last Review: endovascular_therapies_for_extracranial_vertebral_artery_disease

More information

TOBA II 12-Month Results Tack Optimized Balloon Angioplasty

TOBA II 12-Month Results Tack Optimized Balloon Angioplasty TOBA II 12-Month Results Tack Optimized Balloon Angioplasty William Gray, MD System Chief, Cardiovascular Division Main Line Health, Philadelphia, PA Dissection: The Primary Mechanism of Angioplasty Lesions

More information

Open clinical uro-oncology trials in Canada Eric Winquist, MD, George Rodrigues, MD

Open clinical uro-oncology trials in Canada Eric Winquist, MD, George Rodrigues, MD CLINICAL TRIALS Open clinical uro-oncology trials in Canada Eric Winquist, MD, George Rodrigues, MD London Health Sciences Centre, London, Ontario, Canada bladder cancer A PHASE II PROTOCOL FOR PATIENTS

More information

Update interventional Cardiology Hans Rickli St.Gallen

Update interventional Cardiology Hans Rickli St.Gallen Update interventional Cardiology 2012 Hans Rickli St.Gallen 26.11.2012 Review of Literature ESC-Highlights TCT/AHA-Highlights Update interventional cardiology 2012 Structural Heart Disease Transcatheter

More information

Checkpoint Regulators Cancer Immunotherapy takes centre stage. Dr Oliver Klein Department of Medical Oncology 02 May 2015

Checkpoint Regulators Cancer Immunotherapy takes centre stage. Dr Oliver Klein Department of Medical Oncology 02 May 2015 Checkpoint Regulators Cancer Immunotherapy takes centre stage Dr Oliver Klein Department of Medical Oncology 02 May 2015 Adjuvant chemotherapy improves outcome in early breast cancer FDA approval of Imatinib

More information

Clinical: Ipilimumab (MDX-010) Update and Next Steps

Clinical: Ipilimumab (MDX-010) Update and Next Steps Clinical: Ipilimumab (MDX-010) Update and Next Steps Geoffrey M. Nichol, M.D., M.B.A. Senior Vice President, Product Development Medarex, Inc. R&D Day December 9, 2005 Ipilimumab: New Class of Cancer Therapy

More information

Perfomance in Delivering (Commercial Trials)

Perfomance in Delivering (Commercial Trials) Perfomance in Delivering (Commercial Trials) REC Ref IRAS ID Name of Trial Target Of? Minimum Of Maximum Of Target Date To Recruit? Total Date Of to recruit target number Recruited At of patients The Target

More information

Clinical Commissioning Policy Statement: Patent Foramen Ovale (PFO) Closure. April Reference: NHSCB/A09/PS/a

Clinical Commissioning Policy Statement: Patent Foramen Ovale (PFO) Closure. April Reference: NHSCB/A09/PS/a Clinical Commissioning Policy Statement: Patent Foramen Ovale (PFO) Closure April 2013 Reference: NHSCB/A09/PS/a NHS Commissioning Board Clinical Commissioning Policy Statement: Patent Foramen Ovale (PFO)

More information

Checkpoint regulators a new class of cancer immunotherapeutics. Dr Oliver Klein Medical Oncologist ONJCC Austin Health

Checkpoint regulators a new class of cancer immunotherapeutics. Dr Oliver Klein Medical Oncologist ONJCC Austin Health Checkpoint regulators a new class of cancer immunotherapeutics Dr Oliver Klein Medical Oncologist ONJCC Austin Health Cancer...Immunology matters Anti-tumour immune response The participants Dendritc cells

More information

CAROTID ARTERY ANGIOPLASTY

CAROTID ARTERY ANGIOPLASTY CAROTID ARTERY ANGIOPLASTY Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Medical Coverage Guideline

More information

Open clinical uro-oncology trials in Canada George Rodrigues, MD, Mary J. Mackenzie, MD, Eric Winquist, MD

Open clinical uro-oncology trials in Canada George Rodrigues, MD, Mary J. Mackenzie, MD, Eric Winquist, MD Open clinical uro-oncology trials in Canada George Rodrigues, MD, Mary J. Mackenzie, MD, Eric Winquist, MD London Health Sciences Centre, London, Ontario, Canada BLADDER CANCER A MULTICENTRE, RANDOMIZED

More information

Update from Korea on the Lutonix SFA registry 12 month data

Update from Korea on the Lutonix SFA registry 12 month data Update from Korea on the Lutonix SFA registry 12 month data Prospective, Multicenter, Post-Market Registy Assessing the Clinical Use and Safety of the Lutonix Drug Coated Balloon in Femoropopliteal Arteries

More information

ISR-treatment The Leipzig experience with purely mechanical debulking. Sven Bräunlich Department for Angiology University-Hospital Leipzig, Germany

ISR-treatment The Leipzig experience with purely mechanical debulking. Sven Bräunlich Department for Angiology University-Hospital Leipzig, Germany ISR-treatment The Leipzig experience with purely mechanical debulking Sven Bräunlich Department for Angiology University-Hospital Leipzig, Germany Disclosure Speaker name: Sven Bräunlich I have the following

More information

The Clinical Research E-News

The Clinical Research E-News Volume 3: ISSUE 3: February 16, 2011 The Clinical Research E-News Now Open: RTOG 0631, Phase II/III Study of Image-Guided Radiosurgery/SBRT for Localized Spine Metastasis RTOG 1010, A Phase III Trial Evaluating

More information

National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) Trial design:

National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) Trial design: Open clinical uro-oncology trials in Canada Eric Winquist, MD, Mary J. Mackenzie, MD, George Rodrigues, MD London Health Sciences Centre, London, Ontario, Canada BLADDER CANCER A PHASE III STUDY OF IRESSA

More information

Performance in Initiating Clinical Research Q2 2016/17

Performance in Initiating Clinical Research Q2 2016/17 Performance in Initiating Clinical Research Q2 2016/17 Research Ethics Committee Reference Number Integrated Research Application System Number Name of Trial Date of Receipt of Valid Research Application

More information

National Cancer Drugs Fund List - Approved

National Cancer Drugs Fund List - Approved National Cancer Drugs Fund List - Approved DRUG Abiraterone Aflibercet Albumin Bound Paclitaxel Axitinib CDF INDICATION (EXCLUDING APPROVED CRITERIA ) Metastatic Prostate Cancer Metastatic Colorectal Cancer

More information

Open clinical uro-oncology trials in Canada

Open clinical uro-oncology trials in Canada Open clinical uro-oncology trials in Canada Eric Winquist, MD, George Rodrigues, MD London Health Sciences Centre, London, Ontario, Canada bladder cancer A PHASE II PROTOCOL FOR PATIENTS WITH STAGE T1

More information

Summary of Strategic Competitive Analysis and Publication Planning

Summary of Strategic Competitive Analysis and Publication Planning Summary of Strategic Competitive Analysis and Publication Planning Carole Alison Chrvala, PhD 919.545.2149 (Work) 919.951.5230 (Mobile) cchrvala@centurylink.net www.healthmattersmedwriting.com 1 Briefing

More information

Experience of endovascular procedures on abdominal and thoracic aorta in CA region

Experience of endovascular procedures on abdominal and thoracic aorta in CA region Experience of endovascular procedures on abdominal and thoracic aorta in CA region May 14-15, 2015, Dubai Dr. Viktor Zemlyanskiy National Research Center of Emergency Care Astana, Kazakhstan Region Characteristics

More information

6/22/2017 TARGETING THE TARGETS IN 2017 TARGETING THE TARGETS IN 2017

6/22/2017 TARGETING THE TARGETS IN 2017 TARGETING THE TARGETS IN 2017 TARGETING THE TARGETS IN 2017 Primary Care Focus Symposium July 1, 2017 Grace Wang MD I do not have any relevant financial relationships to disclose at this time TARGETING THE TARGETS IN 2017 What are

More information

Studienverzeichnis Medizinische Onkologie

Studienverzeichnis Medizinische Onkologie Studienverzeichnis Medizinische Onkologie Mammakarzinom, Gynäkologie 21/12 24/14 25/14 96/12 PALLAS I I Transdermal CR1447 (4-OH-testosterone) in endocrine responsive-her2 negative and triple negative-androgen

More information

Open and Pending Trials Listing For Arizona Oncology Associates P.C. HOPE Division/ Tucson, Arizona

Open and Pending Trials Listing For Arizona Oncology Associates P.C. HOPE Division/ Tucson, Arizona Open and Pending Trials Listing For Arizona Oncology Associates P.C. HOPE Division/ Tucson, Arizona Solid Tumor: USON 15180 / A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab

More information

Active Cancer Studies by Approval Date For additional information on any one of these studies contact the Lancaster General Cancer Center

Active Cancer Studies by Approval Date For additional information on any one of these studies contact the Lancaster General Cancer Center Active Cancer Studies by Approval Date For additional information on any one of these studies contact the Lancaster General Cancer Center 717-544-3113 PROTOCOL NO STUDY TITLE PRINCIPAL INVESTIGATOR ECOG

More information

NAACR Treatment Webinar Quiz 1

NAACR Treatment Webinar Quiz 1 NAACR Treatment Webinar Quiz 1 1. Which of the following would NOT be considered cancer-directed treatment? a. Hemicolectomy b. Incisional biopsy c. Whole breast radiation d. MRI e. All of the above f.

More information

HSHS St. Vincent Hospital Regional Cancer Center Adult Active Study List

HSHS St. Vincent Hospital Regional Cancer Center Adult Active Study List NHLBI-MDS ECOG-A NCT02775383 Blood Disorders-Other The National Myelodysplastic Syndromes (MDS) Study A221101 ALLIANCE NCT01781468 Brain A Phase III Randomized, Double-Blind Placebo Controlled Study of

More information

Arkansas Health Care Payment Improvement Initiative Percutaneous Coronary Intervention Algorithm Summary

Arkansas Health Care Payment Improvement Initiative Percutaneous Coronary Intervention Algorithm Summary Arkansas Health Care Payment Improvement Initiative Percutaneous Coronary Intervention Algorithm Summary Percutaneous Coronary Intervention (PCI) Algorithm Summary v1.0 Page 2 of 8 Triggers PAP assignment

More information

The Clinical Research E-News

The Clinical Research E-News The Clinical Research E-News Volume 6: ISSUE 5: May 14, 2014 Jefferson Kimmel Cancer Center Network: For urgent clinical trial questions or assistance please page: 877-656-9004 New Featured Trials Actively

More information

NCIC CLINICAL TRIALS GROUP DATA SAFETY MONITORING COMMITTEE Friday, 1 May 2009 SUMMARY REPORT

NCIC CLINICAL TRIALS GROUP DATA SAFETY MONITORING COMMITTEE Friday, 1 May 2009 SUMMARY REPORT NCIC CLINICAL TRIALS GROUP DATA SAFETY MONITORING COMMITTEE Friday, 1 May 2009 SUMMARY REPORT The NCIC CTG DSMC reviewed the following trials with respect to safety, trial conduct, including accrual, and

More information

SUPPLEMENTARY INFORMATION

SUPPLEMENTARY INFORMATION SUPPLEMENTARY NFORMATON n format provided by Melero et al. (AUGUST 2015) Supplementary nformation S3 Combinations including two or more immunotherapy agents based on PD-1/PD-L1 blockade. (Source: https://clinicaltrials.gov/

More information

The Clinical Research E-News

The Clinical Research E-News The Clinical Research E-News Volume 6: ISSUE 5: June 12, 2014 Jefferson Kimmel Cancer Center Network: For urgent clinical trial questions or assistance please page: 877-656-9004 New Featured Trials Actively

More information

Covered Critical Illness Conditions Appendix

Covered Critical Illness Conditions Appendix Covered Critical Illness Conditions Appendix Effective Date: February 1, 2010 This Appendix contains definitions for those Conditions that are covered under the Manulife Financial Group Critical Illness

More information

The Clinical Research E-News

The Clinical Research E-News Volume 2: ISSUE 11: June 2, 2010 The Clinical Research E-News SPECIAL ALERT: The quarterly CRA Meeting will be held at 8:30am on June 16, 2010 at the Bluemle Science Building room 105. Now Open: SWOG0777,

More information

NCIC Clinical Trials Group ASCO Annual Meeting Presentations

NCIC Clinical Trials Group ASCO Annual Meeting Presentations Saturday, June 1 Session Title: Central Nervous System Tumors IND.204 - Poster Board: #3A Phase II study of PX-866 in recurrent glioblastoma. (Abstract #2053) Marshall W. Pitz, MD FRCPC Session Title:

More information

Outcomes Report: Accountability Measures and Quality Improvements

Outcomes Report: Accountability Measures and Quality Improvements Outcomes Report: Accountability Measures and Quality Improvements The s Cancer Committee ensures that patients with cancer are treated according to the nationally accepted measures. Because we are an accredited

More information

Open clinical uro-oncology trials in Canada

Open clinical uro-oncology trials in Canada Open clinical uro-oncology trials in Canada Eric Winquist, MD, George Rodrigues, MD London Health Sciences Centre, London, Ontario, Canada bladder cancer A PHASE II PROTOCOL FOR PATIENTS WITH STAGE T1

More information

including prevention, healthy lifestyle behaviors, populations at risk & disparities (age, race/ ethnicity, gender, geographic & socioeconomic)

including prevention, healthy lifestyle behaviors, populations at risk & disparities (age, race/ ethnicity, gender, geographic & socioeconomic) Endorsement Maintenance 2010 Identification of Gap Areas for which Evidence-based Surgery-related Measures are Needed Cardiac, General, Other Surgical Subspecialties The table below is a tool that identifies

More information

Co-Conveners: Nadia Wise (Adelaide) and Conor Marron (Adelaide) VASCULAR SOCIETY OF INDIA AND RARE VASCULAR DISORDERS (Combined with: Nursing)

Co-Conveners: Nadia Wise (Adelaide) and Conor Marron (Adelaide) VASCULAR SOCIETY OF INDIA AND RARE VASCULAR DISORDERS (Combined with: Nursing) VASCULAR Co-Conveners: Nadia Wise (Adelaide) and Conor Marron (Adelaide) SATURDAY 17 AUGUST 8:30am - 10:00am VASCULAR SOCIETY OF INDIA AND RARE VASCULAR DISORDERS (Combined with: Nursing) Carotid body

More information

Breast Cancer Clinical Trials in Georgia

Breast Cancer Clinical Trials in Georgia www.georgiacore.org www.georgiatrials.org Breast Clinical Trials in Georgia Breast in Georgia: The Facts As the leading cause of cancer incidence among Georgia females, breast cancer accounts for 32 percent

More information

Target date to recruit patients agreed? Target range. maximum. minimum. Date. 5 Agreed 26/01/ /11/2015 Recruitment Finished.

Target date to recruit patients agreed? Target range. maximum. minimum. Date. 5 Agreed 26/01/ /11/2015 Recruitment Finished. No REC Reference IRAS No Title Target number of agreed? Target range minimum Target range maximum Target date to recruit agreed? Planned Recruitment end date Total no of recruited at the agreed target

More information

Immune Checkpoint Inhibitors: The New Breakout Stars in Cancer Treatment

Immune Checkpoint Inhibitors: The New Breakout Stars in Cancer Treatment Immune Checkpoint Inhibitors: The New Breakout Stars in Cancer Treatment 1 Introductions Peter Langecker, MD, PhD Executive Medical Director, Global Oncology Clinipace Worldwide Mark Shapiro Vice President

More information

Summary of Research and Writing Activities in Oncology

Summary of Research and Writing Activities in Oncology Summary of Research and Writing Activities in Oncology Carole Alison Chrvala, PhD 919.545.2149 (Work) 919.951.5230 (Mobile) cchrvala@centurylink.net www.healthmattersmedwriting.com 1 Manuscripts, Posters,

More information

Hu J, Gonsahn MD, Nerenz DR. Socioeconomic status and readmissions: evidence from an urban teaching hospital. Health Aff (Millwood). 2014;33(5).

Hu J, Gonsahn MD, Nerenz DR. Socioeconomic status and readmissions: evidence from an urban teaching hospital. Health Aff (Millwood). 2014;33(5). Appendix Definitions of Index Admission and Readmission Definitions of index admission and readmission follow CMS hospital-wide all-cause unplanned readmission (HWR) measure as far as data are available.

More information

Challenging Genitourinary Tumors: What s New in 2017

Challenging Genitourinary Tumors: What s New in 2017 Challenging Genitourinary Tumors: What s New in 2017 David J. Vaughn, MD Genitourinary Medical Oncology Professor Please note that some of the studies reported in this presentation were presented as an

More information

SAMMPRIS. Stenting and Aggressive Medical Management for Preventing Recurrent Stroke and Intracranial Stenosis. Khalil Zahra, M.D

SAMMPRIS. Stenting and Aggressive Medical Management for Preventing Recurrent Stroke and Intracranial Stenosis. Khalil Zahra, M.D SAMMPRIS Stenting and Aggressive Medical Management for Preventing Recurrent Stroke and Intracranial Stenosis Khalil Zahra, M.D Major points Patients with recent TIA or stroke and intra-cranial artery

More information

The Clinical Research E-News

The Clinical Research E-News Volume 3: ISSUE 2: January 26, 2011 The Clinical Research E-News Now Open: E2208, Randomized Phase II Study of Paclitaxel With or Without the Anti- IGF-IR mab Cixutumumab (IMC-A12) as Second Line Treatment

More information

History of the Powerlink System Design and Clinical Results. Edward B. Diethrich Arizona Heart Hospital Phoenix, AZ

History of the Powerlink System Design and Clinical Results. Edward B. Diethrich Arizona Heart Hospital Phoenix, AZ History of the Powerlink System Design and Clinical Results Edward B. Diethrich Arizona Heart Hospital Phoenix, AZ Powerlink System: Unibody-Bifurcated Design Long Main Body Low-Porosity Proprietary eptfe

More information

Reducing Thrombotic Burden in Arterial Interventions. Mario Galli, MD Cardiovascular Interventional Unit S. Anna Hospital, Como, Italy

Reducing Thrombotic Burden in Arterial Interventions. Mario Galli, MD Cardiovascular Interventional Unit S. Anna Hospital, Como, Italy Reducing Thrombotic Burden in Arterial Interventions Mario Galli, MD Cardiovascular Interventional Unit S. Anna Hospital, Como, Italy Disclosure Speaker name: Mario Galli... I have the following potential

More information

ASCO 2014 Highlights*

ASCO 2014 Highlights* ASCO 214 Highlights* Investor Meeting June 2, 214 *American Society of Clinical Oncology, May 3 June 3, 214 Forward-Looking Information During this meeting, we will make statements about the Company s

More information

The Clinical Research E-News

The Clinical Research E-News Volume 3: ISSUE 5: March 23, 2011 The Clinical Research E-News Now Open: CALGB 90802, Randomized Phase III trial comparing everolimus plus placebo versus everolimus plus bevacizumab for advanced renal

More information

Performance in Initiating Clinical Research Q4 2015/16

Performance in Initiating Clinical Research Q4 2015/16 Performance in Initiating Clinical Research Q4 2015/16 Research Ethics Committee Reference Number Integrated Research Application System Number Name of Trial Date of Receipt of Valid Research Application

More information

The Clinical Research E-News

The Clinical Research E-News The Clinical Research E-News Volume 3: ISSUE 16: September 28, 2011 Jefferson Kimmel Cancer Network: For urgent clinical trial questions or assistance please page: 877-656-9004 Now Open: C70604, A Randomized,

More information

Dr. Sause: Clinical, Research, and Administration. Vilija N. Avizonis, MD Radiation Oncologist; Intermountain Medical Center; Murray, Utah

Dr. Sause: Clinical, Research, and Administration. Vilija N. Avizonis, MD Radiation Oncologist; Intermountain Medical Center; Murray, Utah Dr. Sause: Clinical, Research, and Administration Vilija N. Avizonis, MD Radiation Oncologist; Intermountain Medical Center; Murray, Utah Objectives: Identify Dr. Sause's educational achievements Discuss

More information

REBEL. Platinum Chromium Coronary Stent System. Patient Information Guide

REBEL. Platinum Chromium Coronary Stent System. Patient Information Guide REBEL Patient Information Guide REBEL PATIENT INFORMATION GUIDE You have recently had a REBEL bare metal stent implanted in the coronary arteries of your heart. The following information is important for

More information

Clinical Research Institute HUCH Sponsored, fully signed Clinical Trial Agreements (except grants)

Clinical Research Institute HUCH Sponsored, fully signed Clinical Trial Agreements (except grants) , fully signed Clinical Trial Agreements (except grants) Sponsor Full name of the Hospital clinic where the is details of the January x x January x NightstaRx Ltd A Randomised, Open Label, Outcomes-Assessor

More information

Duration anticoagulation VTE. Clinical case WGA april 2017 Dr Borgoens

Duration anticoagulation VTE. Clinical case WGA april 2017 Dr Borgoens Duration anticoagulation VTE Clinical case WGA april 2017 Dr Borgoens Clinical case 70 y old, sedentary computer engineer 1 st episode intermediate high risk pulmonaryembolism(rv dysfunction, positives

More information

2 Diagnosis and Staging of Cancer 2.1 Pathophysiology of cancer 2.2 Classification and staging 2.3 Diagnostic measures for specific cancer types

2 Diagnosis and Staging of Cancer 2.1 Pathophysiology of cancer 2.2 Classification and staging 2.3 Diagnostic measures for specific cancer types Oncology Nursing Sub-Specialty Module Reference: Gobel B. M., Triest-Robertson S. & Vogel W.H. (Eds). (205). Advanced Oncology Nursing Certificate Review and Resources Manual. Pittsburgh: Oncology Nursing

More information

CY2015 Hospital Outpatient: Endovascular Procedure APCs and Complexity Adjustments

CY2015 Hospital Outpatient: Endovascular Procedure APCs and Complexity Adjustments CY2015 Hospital Outpatient: Endovascular Procedure APCs Complexity Adjustments Comprehensive Ambulatory Payment Classifications (c-apcs) CMS finalized the implementation of 25 Comprehensive APC to further

More information

List of Qualifying Conditions

List of Qualifying Conditions List of Qualifying Conditions Cancer Conditions 1) Adrenal cancer 2) Bladder cancer 3) Bone cancer all forms 4) Brain cancer 5) Breast cancer 6) Cervical cancer 7) Colon cancer 8) Colorectal cancer 9)

More information

Live or Die by the Guidelines: ICD-9-CM

Live or Die by the Guidelines: ICD-9-CM Live or Die by the Guidelines: ICD-9-CM Goals Understand the importance of using ICD-9-CM coding guidelines. 1 Isn t it enough to get paid? Six important reasons to code accurately 1. The inpatient regulatory

More information

Competent Pain Management for Older Patients With Cancer

Competent Pain Management for Older Patients With Cancer Session length: 2 hours, 53 minutes Contact hours: 3.5 Pharmacology hours offered: 30 minutes 2005 ONS Virtual Institutes of Learning Evaluation Form Competent Pain Management for Older Patients With Cancer

More information

Development status of ONO-4538(nivolumab)1

Development status of ONO-4538(nivolumab)1 Development status of ONO-4538(nivolumab)1 Development Code Target Disease JAPAN US/EU KOR/TAI ONO-4538 Melanoma(2 nd ~) Launched Launched (US) Filing (EU) Approved(KOR) Filing(TAI) ONO-4538 Melanoma(1

More information

Open Clinical Trials: What s Out There Now Paula D. Ryan, MD, PhD

Open Clinical Trials: What s Out There Now Paula D. Ryan, MD, PhD Open Clinical Trials: What s Out There Now Paula D. Ryan, MD, PhD Hanahan and Weinberg, 2000 Acquired Capabilities of Cancer Clinical Trials When should I consider a clinical trial? How do I find the right

More information

CancerPACT Cancer Patients Alliance for Clinical Trials

CancerPACT Cancer Patients Alliance for Clinical Trials TM CancerPACT Cancer Patients Alliance for Clinical Trials Listing of Ongoing Cancer Clinical Trials in the Salinas Valley Winter 2008 I. Solid Tumors 1. Breast p.1 2. Central Nervous System p.2 3. Gastrointestinal

More information

Managing Older Patients With Lymphoma and Multiple Myeloma

Managing Older Patients With Lymphoma and Multiple Myeloma 2006 ONS Congress Webcast Evaluation Form Managing Older Patients With Lymphoma and Multiple Myeloma Session length: 1 hour, 45 minutes Contact hours: 1.5 Pharmacology hours offered: 15 minutes How to

More information

Morbidity Audit and Logbook Tool SNOMED Board Reporting Terms for SET and IMG Vascular Surgery AMPUTATION AORTA

Morbidity Audit and Logbook Tool SNOMED Board Reporting Terms for SET and IMG Vascular Surgery AMPUTATION AORTA SNOMED s for SET and IMG Vascular Surgery AMPUTATION Amputation above-knee Amputation of leg through tibia and fibula Amputation of the foot Amputation of toe Through knee amputation Ray amputation of

More information

The Clinical Research E-News

The Clinical Research E-News Volume 3: ISSUE 9: May 18, 2011 The Clinical Research E-News Jefferson Kimmel Cancer Network: For urgent clinical trial questions or assistance please page: 877-656-9004 Now Open: RTOG 0837, A Randomized,

More information

Target date to recruit patients agreed? Target range minimum. Target range maximum. Agreed 1 1 Agreed 01/01/ /01/2016 Recruitment Finished

Target date to recruit patients agreed? Target range minimum. Target range maximum. Agreed 1 1 Agreed 01/01/ /01/2016 Recruitment Finished No REC Reference IRAS No Title Target number of patients agreed? Target range minimum Target range maximum Target date to recruit patients agreed? Planned Recruitment end date No of patients recruited

More information

Chapter 4 Section 9.1

Chapter 4 Section 9.1 Surgery Chapter 4 Section 9.1 Issue Date: August 26, 1985 Authority: 32 CFR 199.4(c)(2) and (c)(3) 1.0 CPT 1 PROCEDURE CODES 33010-33130, 33140, 33141, 33200-37186, 37195-37785, 92950-93272, 93303-93581,

More information

NCCN Guidelines for Prostate Cancer V Web teleconference 06/17/16 and 06/30/17

NCCN Guidelines for Prostate Cancer V Web teleconference 06/17/16 and 06/30/17 Guideline Page and Request PROS-1 Submission from Myriad Genetic Laboratories, Inc. Request addition of recommendation for genetic risk assessment/testing to the Initial Clinical Assessment algorithm for

More information

The Clinical Research E-News

The Clinical Research E-News Volume 3: ISSUE 8: May 5, 2011 The Clinical Research E-News Jefferson Kimmel Cancer Network: For urgent clinical trial questions or assistance please page: 877-656-9004 Now Open: E2906, Phase III randomized

More information

RadRx Your Prescription for Accurate Coding & Reimbursement Copyright All Rights Reserved.

RadRx Your Prescription for Accurate Coding & Reimbursement Copyright All Rights Reserved. Interventional Radiology Coding Case Studies Prepared by Stacie L. Buck, RHIA, CCS-P, RCC, CIRCC, AAPC Fellow President & Senior Consultant Week of November 19, 2018 Abdominal Aortogram, Bilateral Runoff

More information

Novel RCC Targets from Immuno-Oncology and Antibody-Drug Conjugates

Novel RCC Targets from Immuno-Oncology and Antibody-Drug Conjugates Novel RCC Targets from Immuno-Oncology and Antibody-Drug Conjugates Christopher Turner, MD Vice President, Clinical Science 04 November 2016 Uveal Melanoma Celldex Pipeline CANDIDATE INDICATION Preclinical

More information

2016 Year-End Results and Conference Call. March 14, 2017

2016 Year-End Results and Conference Call. March 14, 2017 2016 Year-End Results and Conference Call March 14, 2017 Forward Looking Statement This communication contains "forward-looking" statements within the meaning of the Private Securities Litigation Reform

More information

FACULTY MEMBERSHIP APPLICATION Tulane Cancer Center

FACULTY MEMBERSHIP APPLICATION Tulane Cancer Center FACULTY MEMBERSHIP APPLICATION Tulane Cancer Center 1430 Tulane Ave., Box SL-68, New Orleans, LA 70112-2699 J. Bennett Johnston Building, Mezzanine (Floor 1A), Suite A102 (504) 988-6060, fax (504) 988-6077,

More information

Rotarex mechanical thrombectomythe first line option for thrombotic occlusions?

Rotarex mechanical thrombectomythe first line option for thrombotic occlusions? Rotarex mechanical thrombectomythe first line option for thrombotic occlusions? Dierk Scheinert, MD Division of Interventional Angiology University Hospital Leipzig, Germany Disclosure Advisory Board /Consultant:

More information

Development status of OPDIVO (nivolumab) 1

Development status of OPDIVO (nivolumab) 1 August 1, 2018 Development status of OPDIVO (nivolumab) 1 Target disease JAPAN US/EU KR/TW Melanoma (1 st ) Approved Approved Approved Melanoma (Adjuvant Therapy) Filing Approved (US) Non-small cell lung

More information

2008 Oncology Pharmacy Preparatory Review Course Learning Objectives

2008 Oncology Pharmacy Preparatory Review Course Learning Objectives 2008 Oncology Pharmacy Preparatory Review Course Learning Objectives Session 1 Symptom Management, Part I, II & III Teresa A. Mays, Pharm D., BCOP Director, Investigational Drug Department San Antonio,

More information

Coding Changes for 2018

Coding Changes for 2018 Coding Changes for 2018 An overview of changes to interventional CPT coding that you need to know for practicing in 2018. BY KATHARINE L. KROL, MD, FSIR, FACR There are several coding changes for endovascular

More information

2013 Oncology Pharmacy Specialty Recertification Home Study Syllabus Learning Objectives

2013 Oncology Pharmacy Specialty Recertification Home Study Syllabus Learning Objectives 2013 Oncology Pharmacy Specialty Recertification Home Study Syllabus Learning Objectives Breast Cancer Chad Barnett, Pharm.D., BCOP Clinical Pharmacy Specialist The University of Texas M.D. Anderson Cancer

More information

HSHS St. Vincent Hospital Regional Cancer Center Adult Active Study List

HSHS St. Vincent Hospital Regional Cancer Center Adult Active Study List A031501 ALLIANCE NCT03244384 Bladder Phase III Randomized Adjuvant study of MK-3475 (Pembrolizumab) in muscle invasive and locally advanced urothelial carcinoma (AMBASSADOR) Versus Observation NHLBI-MDS

More information

Peripheral Vascular Disease

Peripheral Vascular Disease Peripheral artery disease (PAD) results from the buildup of plaque (atherosclerosis) in the arteries of the legs. For people with PAD, symptoms may be mild, requiring no treatment except modification of

More information